Overview
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.
Description
Patient data will be collected from medical records after obtaining consent and retrospectively.
Eligibility
Inclusion Criteria:
- Written informed consent must be obtained prior to any data collection.
- Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour
- Aged ≥18 years.
Exclusion Criteria:
- None